CORDIS
EU research results

CORDIS

English EN

European vaccine effort against HIV/AIDS - III

Project information

Grant agreement ID: QLK2-CT-2002-01431

  • Start date

    1 December 2002

  • End date

    31 December 2007

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 3 972 582

  • EU contribution

    € 2 500 000

Coordinated by:

KAROLINSKA INSTITUTE

Sweden

Objective

A vaccine against HIV-1/AIDS is urgently needed to slow down the current epidemic in both Africa and Asia. The predominant subtype of HIV-1 causing the AIDS epidemic in Africa and Asia is subtype C. Clinical lots of priming agents - Gemlike Forest virus (SFV) and naked DNA -, as well as a boosting agent - the attenuated poxvirus strain NYV AC -, are prepared; all vaccine components are derived from HIV-1 subtype C and include the gag, poll, net and envy genes. The objective of the Euro Vac-III demonstration project is to identify the best priming agent, DNA vs. SFV, that allows for reduction of the NYVAC dose without significant loss of immunogenicity. This demonstration project aims for the establishment of the most immunogenic vaccine that is suitable for mass vaccination and forms the last step towards moving into phase IIb and III efficacy trials.

Coordinator

KAROLINSKA INSTITUTE

Address

13,Nobels VÄG 16
171 77 Stockholm

Sweden

Participants (8)

ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

AVENTIS PASTEUR SA

France

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

Spain

IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

United Kingdom

MEDICAL RESEARCH COUNCIL

United Kingdom

MUNICIPAL HEALTH SERVICE

Netherlands

UNIVERSITAET REGENSBURG

Germany

UNIVERSITY OF LAUSANE

Switzerland

Project information

Grant agreement ID: QLK2-CT-2002-01431

  • Start date

    1 December 2002

  • End date

    31 December 2007

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 3 972 582

  • EU contribution

    € 2 500 000

Coordinated by:

KAROLINSKA INSTITUTE

Sweden